Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q3

3151.TEDINET S100Q4CC
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥443.2bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥439.3bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥1.9bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥2.1bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥4.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥4.1bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥2.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥336.1bnat 2022-12-31Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥346.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥233.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥102.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥101.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥35.2bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥46.592022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.222022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.842021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥236m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥126m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-12-31¥426.2bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-12-31¥418.3bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥6m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥77m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥276m
—segment totalrevenue2022-04-01 → 2022-12-31¥448.2bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥440.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥453.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥443.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥119m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31¥36m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2021-04-01 → 2021-12-31¥421.5bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2021-04-01 → 2021-12-31¥414.9bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥162m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥318m
—segment totalrevenue2021-04-01 → 2021-12-31¥443.1bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥436.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥447.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥439.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 374
ItemContextValueUnit
Profit lossPrior1YTDDuration2536000000JPY
Profit lossCurrentYTDDuration2510000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration88000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration77000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration2448000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2433000000JPY
Profit lossPrior1YTDDuration2536000000JPY
Profit lossCurrentYTDDuration2510000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-2629000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2416000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-291000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-267000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration-169000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration81000000JPY
Other comprehensive incomePrior1YTDDuration-3091000000JPY
Other comprehensive incomeCurrentYTDDuration2230000000JPY
Comprehensive incomePrior1YTDDuration-554000000JPY
Comprehensive incomeCurrentYTDDuration4740000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-642000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration4663000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration88000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration77000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember414895000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember13791000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember7850000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember436537000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember2791000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember439329000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration439329000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember6611000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember1000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember6613000000JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1859000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember8472000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-8472000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember421507000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember13792000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember7850000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember443150000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember4651000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember447801000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-8472000000JPY
Net salesPrior1YTDDuration439329000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember1688000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember162000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember318000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember2169000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass